Latest Headlines

Latest Headlines

Roche looks to shake up the MS market with some promising Phase III data

Roche's much-hyped multiple sclerosis treatment ocrelizumab kept up its momentum with the release of detailed late-stage data, burnishing hopes the injected drug is a blockbuster in the making.

Boston Scientific tests the waters with a remote patient monitoring innovation challenge

Remote patient monitoring isn't a core business for Boston Scientific, but it is looking to gain access to the most cutting-edge tech in the field. It's launched the Boston Scientific Connected Patient Challenge: an open innovation challenge to solicit ideas and collaborations for remote patient monitoring.

Harvard's Wyss launches Opsonix, backed by Baxter in $8M round to get sepsis device into clinic

The Wyss Institute for Biologically Inspired Engineering at Harvard University has launched startup Opsonix to develop its pathogen-extracting, extracorporeal sepsis device. Hansjörg Wyss, who founded the Institute with a $125 million gift in 2008, also participated in an $8 million Series A round that was led by Baxter Ventures.

INC bolsters its Phase I platform with new cardiac tech

INC Research added a new tool for early-stage safety studies, bringing in a new technology the company says will make Phase I cardiac trials more efficient.

Experts push for trials to evaluate Roche, GSK flu drugs' pandemic potential

Critics have long questioned the effectiveness of Roche and GlaxoSmithKline's flu drugs, asking whether their benefits justify the estimated $2 billion spent to stockpile them for potential epidemics. Now, heading into flu season, scientists have an answer: No one knows. 

PPD signs a pair of federal deals for battlefield health, flu readiness

Privately held CRO PPD scored two federal contracts tasking it with helping to improve health outcomes for active-duty soldiers and aiding with the government's stockpile of flu vaccines.

Wyss spins out pathogen-capturing tech into upstart biotech

Harvard's Wyss Institute is spinning out another biotech. The cutting-edge research group has launched Opsonix with $8 million from Baxter Ventures and Hansjörg Wyss, the Swiss billionaire who founded the institute.

Belgian CRO genae reaches into Asia with new Tokyo hub

Genae, a med tech-focused CRO, opened a Japanese outpost to broaden its reach, setting up shop in Tokyo with eyes on the growing Asian market for medical devices.

Evotec inks a $4.9M deal for oncology R&D

German drug developer Evotec signed a 5-year, $4.9 million agreement with the National Cancer Institute to help the group build and manage its library of potential oncology drugs.

BARDA provides funding to Vaxart, U. of Cambridge for flu vaccine improvements

As part of its responsibility to prepare for public health threats, the U.S. Department of Health and Human Services' BARDA unit is seeking more effective influenza vaccines to incorporate into its pandemic strategy. Now, it's funding two projects it hopes will help the state of affairs.